Roivant Sciences Ltd (ROIV) concluded trading on Thursday at a closing price of $10.97, with 15.48 million shares of worth about $169.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.96% during that period and on March 20, 2025 the price saw a gain of about 0.27%. Currently the company’s common shares owned by public are about 719.63M shares, out of which, 437.29M shares are available for trading.
Stock saw a price change of 5.28% in past 5 days and over the past one month there was a price change of 2.81%. Year-to-date (YTD), ROIV shares are showing a performance of -7.27% which increased to 11.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.80 but also hit the highest price of $13.06 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 4.89 million. The stock is currently trading 3.43% above its 20-day simple moving average (SMA20), while that difference is up 1.60% for SMA50 and it goes to -3.09% lower than SMA200.
Roivant Sciences Ltd (NASDAQ: ROIV) currently have 719.63M outstanding shares and institutions hold larger chunk of about 68.68% of that.
The stock has a current market capitalization of $7.83B and its 3Y-monthly beta is at 1.22. It has posted earnings per share of -$0.14 in the same period. It has Quick Ratio of 37.91 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 4.66% while standing at 3.54% over the month.
Stock’s fiscal year EPS is expected to drop by -105.88% while it is estimated to decrease by -263.90% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on February 15, 2024 offering an Outperform rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Roivant Sciences Ltd (ROIV) stock as an Overweight in their note to investors on January 05, 2024, suggesting a price target of $20 for the stock. On December 12, 2023, Deutsche Bank Initiated their recommendations, while on October 17, 2023, Guggenheim Initiated their ratings for the stock with a price target of $17. Stock get a Neutral rating from BofA Securities on June 08, 2023.
